Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
2019; Lippincott Williams & Wilkins; Volume: 74; Issue: 2 Linguagem: Inglês
10.1097/01.ogx.0000552695.03241.d6
ISSN1533-9866
AutoresKathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González‐Martín, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro,
Tópico(s)Ovarian cancer diagnosis and treatment
Resumo(Abstracted from N Engl J Med 2018;379:2495–2505) Standard-of-care therapy for patients newly diagnosed with advanced ovarian cancer consists of frontline cytoreductive surgery and adjuvant platinum chemotherapy. Approximately 70% of these patients have a relapse within 3 years.
Referência(s)